134 related articles for article (PubMed ID: 38325713)
1. Metabolomics and lipidomics in non-small cell lung cancer.
Shi W; Cheng Y; Zhu H; Zhao L
Clin Chim Acta; 2024 Mar; 555():117823. PubMed ID: 38325713
[TBL] [Abstract][Full Text] [Related]
2. Characterization of chemoresistant human non-small cell lung cancer cells by metabolic and lipidomic profiling.
Lee JW; Lee H; Chun YS; Ahn J; Moon JY; Kim DK; Cho SK; Choi HK
Metabolomics; 2023 Sep; 19(9):80. PubMed ID: 37690093
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.
Ruiying C; Zeyun L; Yongliang Y; Zijia Z; Ji Z; Xin T; Xiaojian Z
PLoS One; 2020; 15(5):e0232272. PubMed ID: 32374740
[TBL] [Abstract][Full Text] [Related]
4. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.
Noreldeen HAA; Du L; Li W; Liu X; Wang Y; Xu G
J Pharm Biomed Anal; 2020 Jun; 185():113220. PubMed ID: 32145537
[TBL] [Abstract][Full Text] [Related]
5. Assessment of plasma amino acids, purines, tricarboxylic acid cycle metabolites, and lipids levels in NSCLC patients based on LC-MS/MS quantification.
Cang S; Liu R; Mu K; Tang Q; Cui H; Bi K; Zhang Y; Li Q
J Pharm Biomed Anal; 2022 Nov; 221():114990. PubMed ID: 36208488
[TBL] [Abstract][Full Text] [Related]
6. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer.
Sun R; Fei F; Wang M; Jiang J; Yang G; Yang N; Jin D; Xu Z; Cao B; Li J
Cancer Med; 2023 Sep; 12(18):19245-19259. PubMed ID: 37605514
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.
Cao P; Wu S; Guo W; Zhang Q; Gong W; Li Q; Zhang R; Dong X; Xu S; Liu Y; Shi S; Huang Y; Zhang Y
Metabolomics; 2021 Nov; 17(11):98. PubMed ID: 34729658
[TBL] [Abstract][Full Text] [Related]
9. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
10. Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation.
Hu JM; Sun HT
Radiat Oncol; 2018 Mar; 13(1):40. PubMed ID: 29530051
[TBL] [Abstract][Full Text] [Related]
11. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
12. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
13. Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer.
Chen Y; Ma Z; Shen X; Li L; Zhong J; Min LS; Xu L; Li H; Zhang J; Dai L
Biomed Res Int; 2018; 2018():5276240. PubMed ID: 30175133
[TBL] [Abstract][Full Text] [Related]
14. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
[TBL] [Abstract][Full Text] [Related]
16. Clinical lipidomics in understanding of lung cancer: Opportunity and challenge.
Zhang L; Zhu B; Zeng Y; Shen H; Zhang J; Wang X
Cancer Lett; 2020 Feb; 470():75-83. PubMed ID: 31655086
[TBL] [Abstract][Full Text] [Related]
17. Metabolic network-based identification of plasma markers for non-small cell lung cancer.
Guo L; Li L; Xu Z; Meng F; Guo H; Liu P; Liu P; Tian Y; Xu F; Zhang Z; Zhang S; Huang Y
Anal Bioanal Chem; 2021 Dec; 413(30):7421-7430. PubMed ID: 34617154
[TBL] [Abstract][Full Text] [Related]
18. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.
Puchades-Carrasco L; Jantus-Lewintre E; Pérez-Rambla C; García-García F; Lucas R; Calabuig S; Blasco A; Dopazo J; Camps C; Pineda-Lucena A
Oncotarget; 2016 Mar; 7(11):12904-16. PubMed ID: 26883203
[TBL] [Abstract][Full Text] [Related]
19. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics in the development and progression of rheumatoid arthritis: A systematic review.
Li C; Chen B; Fang Z; Leng YF; Wang DW; Chen FQ; Xu X; Sun ZL
Joint Bone Spine; 2020 Oct; 87(5):425-430. PubMed ID: 32473419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
